Journal article
Efficacy and Safety of Fondaparinux Versus Enoxaparin in Patients With Acute Coronary Syndromes Treated With Glycoprotein IIb/IIIa Inhibitors or Thienopyridines Results From the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) Trial
Abstract
OBJECTIVES: This study sought to evaluate the relative safety and efficacy of fondaparinux and enoxaparin in patients with acute coronary syndromes (ACS) treated with glycoprotein (GP) IIb/IIIa inhibitors or thienopyridines.
BACKGROUND: The OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial showed that fondaparinux reduced major bleeding by 50% compared with enoxaparin while preserving similar efficacy. Whether this …
Authors
Jolly SS; Faxon DP; Fox KAA; Afzal R; Boden WE; Widimsky P; Steg PG; Valentin V; Budaj A; Granger CB
Journal
Journal of the American College of Cardiology, Vol. 54, No. 5, pp. 468–476
Publisher
Elsevier
Publication Date
July 2009
DOI
10.1016/j.jacc.2009.03.062
ISSN
0735-1097